ArticleEJHaem2025
Gain/Amplification 17p as a Potential Favorable Prognostic Factor in Multiple Myeloma: A Real-World Settings Retrospective Study.
Article in EJHaem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple myeloma (MM) is a genetically heterogeneous malignancy in which cytogenetic abnormalities critically influence prognosis. The prognostic significance of 17p gain/amplification (17p+), particularly relative to del(17p) and the high-risk 1q21 gain/amplification (1q21+), remains insufficiently defined. Methods: We retrospectively analyzed 125 MM patients treated at a single center between 2015 and 2024. Cytogenetic profiles were assessed using fluorescence in situ hybridization (FISH). Kaplan-Meier curves and Cox proportional hazards models evaluated the impact of 17p+ on progression-free survival 1 (PFS1), time to next treatment (TTNT), and overall survival (OS). Results: Compared with del(17p), 17p+ was associated with significantly longer PFS1 (HR 0.21, Conclusions: 17p+ is associated with markedly improved clinical outcomes in MM and may partially mitigate the adverse prognostic impact of 1q21+. These findings highlight the relevance of 17p+ in cytogenetic risk stratification and personalized treatment strategies and support further validation in multicenter cohorts. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.